Last reviewed · How we verify
NSAI treatment
NSAI treatment inhibits nonsteroidal anti-inflammatory agents to reduce inflammation and associated symptoms.
NSAI treatment inhibits nonsteroidal anti-inflammatory agents to reduce inflammation and associated pain. Used for Inflammatory conditions (specific indication unclear from available information).
At a glance
| Generic name | NSAI treatment |
|---|---|
| Also known as | Fenbid gel |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and/or COX-2) |
| Modality | Small molecule |
| Therapeutic area | Inflammation, Pain Management |
| Phase | FDA-approved |
Mechanism of action
NSAIs (nonsteroidal anti-inflammatory drugs) work by inhibiting cyclooxygenase (COX) enzymes, which reduces the production of prostaglandins and other inflammatory mediators. This mechanism decreases inflammation, pain, and fever across various conditions. The exact formulation and specific COX selectivity depend on the particular NSAI compound being referenced.
Approved indications
- Inflammatory conditions and pain management
- Potentially fever reduction in infectious diseases (context-dependent on LSHTM research focus)
Common side effects
- Gastrointestinal upset
- Dyspepsia
- Nausea
- Increased cardiovascular risk (with chronic use)
- Renal impairment (with chronic use)
Key clinical trials
- A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (PHASE3)
- Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (PHASE2)
- Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (PHASE3)
- Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer (PHASE3)
- An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer
- Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (PHASE2)
- Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer (PHASE2)
- Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NSAI treatment CI brief — competitive landscape report
- NSAI treatment updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI